Cargando…

Mechanisms of action and antimicrobial activity of ceftobiprole

Ceftobiprole, a novel last generation parenteral cephalosporin, has an extended spectrum of activity, notably against methicillin-resistant Staphylococcus aureus (MRSA), ampicillin-susceptible enterococci, penicillinresistant pneumococci, Enterobacterales and susceptible Pseudomonas aeruginosa. It e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morosini, María-Isabel, Díez-Aguilar, María, Cantón, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedad Española de Quimioterapia 2019
Materias:	Ceftobiprole Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755350/ https://www.ncbi.nlm.nih.gov/pubmed/31364335

Ejemplares similares

Safety and tolerability of ceftobiprole
por: Grau, Santiago
Publicado: (2019)

Ceftobiprole for the treatment of pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2019)

Possible clinical indications of ceftobiprole
por: Barberán, José
Publicado: (2019)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

Ceftobripole: Experience in staphylococcal bacteremia
por: Soriano, Alex, et al.
Publicado: (2019)

Introduction
por: Llinares, Pedro, et al.
Publicado: (2019)

In vitro activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016–19)
por: Canton, Rafael, et al.
Publicado: (2022)

Ceftobiprole medocaril
por: Méndez, Raúl, et al.
Publicado: (2022)

Ceftobiprole: a clinical view
por: Pérez-Crespo, Pedro María Martínez, et al.
Publicado: (2021)

Ceftobiprole for the treatment of pneumonia: a European perspective
por: Liapikou, Adamantia, et al.
Publicado: (2015)

Ceftobiprole Perspective: Current and Potential Future Indications
por: Lupia, Tommaso, et al.
Publicado: (2021)

Changes in bacterial hospital epidemiology
por: Morosini, María Isabel, et al.
Publicado: (2019)

Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Emerging agents to combat complicated and resistant infections: focus on ceftobiprole
por: Bustos, César, et al.
Publicado: (2010)

Evaluation of Rapid Polymyxin Pseudomonas test in clinical Pseudomonas aeruginosa isolates with various degrees of multidrug resistance
por: Sánchez-López, Javier, et al.
Publicado: (2021)

In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile
por: Binyamin, Dana, et al.
Publicado: (2018)

Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole
por: Barbour, April, et al.
Publicado: (2010)

2162. In Vitro Antimicrobial Activity of Ceftobiprole against Streptococcus pneumoniae Isolates from the United States (2016–2020)
por: Duncan, Leonard R, et al.
Publicado: (2023)

Establishing Antimicrobial Susceptibility Testing Methods and Clinical Breakpoints for Inhaled Antibiotic Therapy
por: Ekkelenkamp, Miquel B, et al.
Publicado: (2022)

Pharmacokinetics and Target Attainment of Ceftobiprole in Asian and Non‐Asian Subjects
por: Muller, A. E., et al.
Publicado: (2018)

Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Antimicrobial activity of ceftobiprole and comparator agents when tested against gram-positive and -negative organisms collected across China (2016–2018)
por: Dandan, Yin, et al.
Publicado: (2022)

Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations
por: Torres, Antonio, et al.
Publicado: (2016)

Ceftobiprole for Treatment of MRSA Blood Stream Infection: A Case Series
por: Mahmoud, Ebrahim, et al.
Publicado: (2020)

Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016)
por: Flamm, Robert K, et al.
Publicado: (2017)

New microbiological aspects of fosfomycin
por: Díez-Aguilar, María, et al.
Publicado: (2019)

Hypermucoviscous Klebsiella pneumoniae: A challenge in community acquired infection
por: Sánchez-López, Javier, et al.
Publicado: (2019)

Antimicrobial peptides: mechanism of action, activity and clinical potential
por: Zhang, Qi-Yu, et al.
Publicado: (2021)

Ceftobiprole: a potential empirical post-operative monotherapy in prosthetic joint infections
por: Duployez, Claire, et al.
Publicado: (2020)

Capsicum fruits as functional ingredients with antimicrobial activity: an emphasis on mechanisms of action
por: Romero-Luna, Haydee Eliza, et al.
Publicado: (2022)

No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials
por: Hamed, Kamal, et al.
Publicado: (2020)

Pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose intravenous ceftobiprole in healthy Chinese participants
por: Li, Wan-Zhen, et al.
Publicado: (2021)

Synergistic Combinations of FDA-Approved Drugs with Ceftobiprole against Methicillin-Resistant Staphylococcus aureus
por: Sharma, Amar Deep, et al.
Publicado: (2022)

Ampicillin and Ceftobiprole Combination for the Treatment of Enterococcus faecalis Invasive Infections: “The Times They Are A-Changin”
por: Giuliano, Simone, et al.
Publicado: (2023)

Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013–2015
por: Henriksen, Anne Santerre, et al.
Publicado: (2018)

1946. In Vitro Activity of Ceftobiprole against Staphylococcus aureus Bacteremia Isolates from the United States (2018–2020)
por: Duncan, Leonard R, et al.
Publicado: (2023)

Antimicrobial Peptides—Mechanisms of Action, Antimicrobial Effects and Clinical Applications
por: Talapko, Jasminka, et al.
Publicado: (2022)

Cefto Real-Life Study: Real-World Data on the Use of Ceftobiprole in a Multicenter Spanish Cohort
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2023)

Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015
por: Santerre Henriksen, Anne, et al.
Publicado: (2018)

No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials [Erratum]
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ps6bd6e5mqspcbib5d0gshggpu